Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Radiation. Centre Hospitalier de l'Université de Montréal, Montreal, Canada



Survival: 59.8 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Radiation
   
Drugs:
Country: Canada
   
City/State/Province: Montreal
   
Hospital: Centre Hospitalier de l'Université de Montréal
   
Journal: Link
   
Date: 4/2014

Description:
Patients:
This study involved 93 indolent non-Hodgkin lymphoma patients who had received prior rituximab-based biologic therapy. The median patient age was 59 years and 53.8% were male.

Treatment:
Patients received biologic therapy with tositumomab (a monoclonal antibody that binds to the CD20 protein on the surface of lymphoma cells) and radiation therapy with I131-tositumomab (radiation-labeled form of tositumomab).

Toxicities:
Treatment-related deaths due to infection, respiratory failure, and myelodysplastic syndrome (MDS) were reported, as was grade 3-4 fatigue, shortness of breath, and pain.

Results:
The median overall survival was 59.8 months.

Support:
This study was funded by GlaxoSmithKline, Inc.

Correspondence: Dr. Harold J. Olney; email: harold.olney.chum@ssss.gouv.qc.ca

E-mail to a Friend Email Physician More Information